Clinical trials have demonstrated that the anti-inflammatory treatments with agents such as antiendotoxin antibodies [19, 20], monoclonal antibodies against TNF [21, 22], soluble TNF receptors [23, 24], IL-1 receptor antagonist [18, 25], PAF antagonists [26, 27], or a nonselective NOS inhibitor [28] have failed to improve the outcome of patients with severe sepsis. The gene discussed is TNF; the disease is Sepsis.